BioSpace News Archive

Tarsius Pharma Awarded €2.4 Million EU Grant to Support First-in-human Clinical Trial for TRS01

Tarsius Pharma, a company developing a breakthrough platform technology for the treatment of blinding ocular diseases, has been awarded a highly competitive HRIZON 2020 Grant from the European Commission worth 2.4 million EUR (~$2.6 million).

September 16, 2019
·
2 min read
Business

Elekta Awarded Sole Source Agreement With Premier

Elekta (EKTA-B.ST) has been awarded a group purchasing agreement for Full Line Radiation Oncology Products and Services with Premier.

September 16, 2019
·
3 min read
Tantalus Labs Launches Proprietary Limited Release Cannabis Cultivar

Tantalus Labs Ltd. (“Tantalus Labs”), a B.C.-based licensed cannabis producer known for their proprietary genetics and established product lines, have expanded their offerings into a new, exclusive and limited release cannabis product

September 16, 2019
·
4 min read
BioMidwest

Merieux NutriSciences Receives Non-GMO Project Approval

Mérieux NutriSciences, a leader in global food safety and quality, receives official approval from the Non-GMO Project, a nonprofit organization whose mission is to preserve and build sources of non-GMO products as part of the Non-GMO Project Approved Laboratory Program.

September 16, 2019
·
1 min read
Saluda Medical Announces European Commercial Launch of Evoke®, the First and Only ECAP-Controlled, Closed-Loop SCS System for Chronic Pain Relief

World’s First Commercial Implants of the Evoke System Completed in The Netherlands

September 16, 2019
·
3 min read
Pharm Country

Dr. Reddy’s Announces the Launch of Over-the-Counter, Store-Brand Equivalent of Prevacid® 24HR Capsules (Lansoprazole Delayed-Release Capsules USP, 15 mg) in the U.S. Market

Dr. Reddy’s Laboratories Ltd. announced the launch of Lansoprazole Delayed-Release Capsules USP, 15 mg, an over-the-counter (OTC) store-brand equivalent of Prevacid® 24HR Capsules, in the United States market, as approved by the U.S. Food and Drug Administration (USFDA).

September 16, 2019
·
3 min read
Job Trends

Susan G. Komen® Unveils $26 Million Investment in Research, Focused on Metastatic Breast Cancer and New Treatments

Susan G. Komen® announced $26 million in funding for new research projects that focus on metastatic breast cancer, developing new, more-effective treatments, and addressing disparities in breast cancer outcomes.

September 16, 2019
·
4 min read
Policy

China NMPA Accepts Clinical Trial Application For CASI’s CD19 CAR-T-Product

CASI Pharmaceuticals, Inc. announces that the Chinese National Medical Product Administration, the Chinese FDA, has accepted the clinical trial application for CNCT19 for investigation in relapsed B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.

September 16, 2019
·
5 min read
Policy

Gala Therapeutics Receives FDA Breakthrough Device Designation for the Minimally Invasive RheOx™ System for Chronic Bronchitis

Gala Therapeutics, Inc., a developer of medical devices to treat pulmonary disease, announced the U.S. Food and Drug Administration granted Breakthrough Device Designation for the RheOxTM Bronchial RheoplastyTM system.

September 16, 2019
·
2 min read
FDA

Tiziana Life Sciences Announces FDA Approval to Initiate Phase I Clinical Trial with Orally Administered Foralumab in Healthy Volunteers

A breakthrough approach for treatment of autoimmune and inflammatory diseases

September 16, 2019
·
7 min read